With the data obtained in this study, we believe that new therapeutic strategies based on TLR4 inhibitors or prebiotics will become an essential target for treating type 1 diabetes and other diseases associated with hypercortisolism in the future. Here, TLR4 is linked to adrenal gland hyperfunction.